{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:04:54Z","timestamp":1789434294187,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":84,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Scientific and Technological Research Council of T\u00dcRK\u0130YE","award":["Project No: 123Z077"],"award-info":[{"award-number":["Project No: 123Z077"]}]},{"name":"\u00c7anakkale Onsekiz Mart University The Scientific Research Coordination Unit","award":["TYL-2022-3990"],"award-info":[{"award-number":["TYL-2022-3990"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-59015-7","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:39:11Z","timestamp":1782196751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Discovery of potential AXL inhibitors using virtual screening, molecular docking, molecular dynamics, molecular mechanics, and in vitro validation"],"prefix":"10.1038","volume":"16","author":[{"given":"Nebahat","family":"Sahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Onder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nermin","family":"Kahraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayra","family":"Dilmac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Ozpolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4037-1979","authenticated-orcid":false,"given":"Ferah","family":"Comert Onder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"59015_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"59015_CR2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043","author":"RL Siegel","year":"2026","unstructured":"Siegel, R. L., Kratzer, T. B., Wagle, N. S., Sung, H. & Jemal, A. Cancer statistics. CA Cancer J. Clin. https:\/\/doi.org\/10.3322\/caac.70043 (2026).","journal-title":"CA Cancer J. Clin."},{"key":"59015_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature 575, 299\u2013309 (2019).","journal-title":"Nature"},{"key":"59015_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.lfs.2018.02.033","volume":"198","author":"Y Shen","year":"2018","unstructured":"Shen, Y., Chen, X., He, J., Liao, D. & Zu, X. Axl inhibitors as novel cancer therapeutic agents. Life Sci. 198, 99\u2013111 (2018).","journal-title":"Life Sci."},{"key":"59015_CR5","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1080\/07391102.2020.1742791","volume":"39","author":"L Nagamalla","year":"2021","unstructured":"Nagamalla, L. & Kumar, J. S. In silico screening of FDA approved drugs on AXL kinase and validation for breast cancer cell line. J. Biomol. Struct. Dyn. 39, 2056\u20132070 (2021).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"59015_CR6","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1038\/sj.onc.1203957","volume":"19","author":"DR Robinson","year":"2000","unstructured":"Robinson, D. R., Wu, Y. M. & Lin, S. F. The protein tyrosine kinase family of the human genome. Oncogene 19, 5548\u20135557 (2000).","journal-title":"Oncogene"},{"key":"59015_CR7","first-page":"222","volume":"99","author":"P Li","year":"2022","unstructured":"Li, P. et al. Identification of an AXL kinase inhibitor in triple-negative breast cancer by structure-based virtual screening and bioactivity test Chem. Biol. Drug Des. 99, 222\u2013232 (2022).","journal-title":"Biol. Drug Des."},{"key":"59015_CR8","doi-asserted-by":"publisher","first-page":"8419","DOI":"10.3390\/ijms21228419","volume":"21","author":"I Falcone","year":"2020","unstructured":"Falcone, I. et al. AXL receptor in breast cancer: Molecular involvement and therapeutic limitations. Int J. Mol. Sci. 21, 8419 (2020).","journal-title":"Int J. Mol. Sci."},{"key":"59015_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-024-02121-7","volume":"10","author":"M Yadav","year":"2025","unstructured":"Yadav, M. et al. AXL signaling in cancer: from molecular insights to targeted therapies. Signal Transduction Target Ther. 10, 37 (2025).","journal-title":"Signal Transduction Target Ther."},{"key":"59015_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13046-023-02726-w","volume":"42","author":"Y Tang","year":"2023","unstructured":"Tang, Y., Zang, H., Wen, Q. & Fan, S. AXL in cancer: a modulator of drug resistance and therapeutic target. J. Exp. Clin. Cancer Res. 42, 148 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"59015_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","volume":"18","author":"C Zhu","year":"2019","unstructured":"Zhu, C., Wei, Y. & Wei, X. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol. Cancer 18, 153 (2019).","journal-title":"Mol. Cancer"},{"key":"59015_CR12","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1158\/0008-5472.CAN-24-3841","volume":"85","author":"M Eriksen Gjerstad","year":"2025","unstructured":"Eriksen Gjerstad, M., Aehnlich, P., Gelebart, P. & McCormack, E. AXL tyrosine kinases: a growing isoform family that promotes cancer pathogenesis. Cancer Res. 85, 2561\u20132573 (2025).","journal-title":"Cancer Res."},{"key":"59015_CR13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41571-023-00813-7","volume":"20","author":"D DeRyckere","year":"2023","unstructured":"DeRyckere, D., Huelse, J. M., Earp, H. S. & Graham, D. K. TAM family kinases as therapeutic targets at the interface of cancer and immunity. Nat. Rev. Clin. Oncol. 20, 755\u2013779 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"59015_CR14","doi-asserted-by":"publisher","first-page":"874","DOI":"10.18632\/oncotarget.360","volume":"2","author":"M Dufies","year":"2011","unstructured":"Dufies, M. et al. Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Oncotarget 2, 874\u2013885 (2011).","journal-title":"Oncotarget"},{"key":"59015_CR15","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/1535-7163.MCT-22-0617","volume":"22","author":"R Ozyurt","year":"2023","unstructured":"Ozyurt, R. & Ozpolat, B. Therapeutic landscape of AXL receptor kinase in triple-negative breast cancer. Mol Cancer Ther. 22, 818\u2013832 (2023).","journal-title":"Mol Cancer Ther."},{"key":"59015_CR16","doi-asserted-by":"publisher","first-page":"108824","DOI":"10.1016\/j.bioorg.2025.108824","volume":"164","author":"BD Sathe","year":"2025","unstructured":"Sathe, B. D. et al. Dual inhibition of AXL and MER kinase: scope for lung and breast cancer therapeutics. Bioorg. Chem. 164, 108824 (2025).","journal-title":"Bioorg. Chem."},{"key":"59015_CR17","doi-asserted-by":"publisher","first-page":"6792","DOI":"10.3390\/ijms26146792","volume":"26","author":"E Biltekin","year":"2025","unstructured":"Biltekin, E. et al. Inhibition of FOXM1 leads to suppression of cell proliferation, migration, and invasion through AXL\/eEF2 kinase signaling and induces apoptosis and ferroptosis in GBM cells. Int. J. Mol. Sci. 26, 6792 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"59015_CR18","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.bmcl.2016.12.024","volume":"27","author":"W Keung","year":"2017","unstructured":"Keung, W. et al. Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate Bioorg. Med. Chem. Lett. 27, 1099\u20131104 (2017).","journal-title":"Med. Chem. Lett."},{"key":"59015_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jcp.20265","volume":"204","author":"PP Sainaghi","year":"2005","unstructured":"Sainaghi, P. P. et al. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J. Cell. Physiol. 204, 36\u201344 (2005).","journal-title":"J. Cell. Physiol."},{"key":"59015_CR20","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1158\/0008-5472.CAN-07-2661","volume":"68","author":"YX Zhang","year":"2008","unstructured":"Zhang, Y. X. et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res. 68, 1905\u20131915 (2008).","journal-title":"Cancer Res."},{"key":"59015_CR21","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.3390\/ijms26072957","volume":"26","author":"D Romaniello","year":"2025","unstructured":"Romaniello, D., Morselli, A. & Marrocco, I. Strategies to overcome resistance to osimertinib in EGFR-mutated lung cancer. Int. J. Mol. Sci. 26, 2957 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"59015_CR22","doi-asserted-by":"publisher","first-page":"618","DOI":"10.4161\/cbt.8.7.7923","volume":"8","author":"JBM Koorstra","year":"2009","unstructured":"Koorstra, J. B. M. et al. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol. Ther. 8, 618\u2013626 (2009).","journal-title":"Cancer Biol. Ther."},{"key":"59015_CR23","doi-asserted-by":"publisher","first-page":"e013186","DOI":"10.1136\/jitc-2025-013186","volume":"13","author":"K Ashouri","year":"2025","unstructured":"Ashouri, K. et al. Clinical and molecular characterization of AXL in colorectal cancer: CALGB (Alliance)\/SWOG 80405 and real-world data. J. Immunother. Cancer 13, e013186 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"59015_CR24","doi-asserted-by":"publisher","first-page":"104005","DOI":"10.1016\/j.drudis.2024.104005","volume":"29","author":"L De Rosa","year":"2024","unstructured":"De Rosa, L., Di Stasi, R., Fusco, V. & D\u2019Andrea, L. D. AXL receptor as an emerging molecular target in colorectal cancer. Drug Discov. Today 29, 104005 (2024).","journal-title":"Drug Discov. Today"},{"key":"59015_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1158\/0008-5472.CAN-12-3151","volume":"73","author":"J Hong","year":"2013","unstructured":"Hong, J., Peng, D., Chen, Z., Sehdev, V. & Belkhiri, A. ABL regulation by AXL promotes cisplatin resistance in esophageal cancer. Cancer Res. 73, 331\u2013340 (2013).","journal-title":"Cancer Res."},{"key":"59015_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1159\/000079499","volume":"66","author":"W Sun","year":"2004","unstructured":"Sun, W., Fujimoto, J. & Tamaya, T. Coexpression of Gas6\/Axl in human ovarian cancers. Oncology 66, 450\u2013457 (2004).","journal-title":"Oncology"},{"key":"59015_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.omtn.2017.06.023","volume":"9","author":"P Kanlikilicer","year":"2017","unstructured":"Kanlikilicer, P. et al. Therapeutic targeting of AXL Receptor tyrosine kinase inhibits tumor growth and intraperitoneal metastasis in ovarian cancer. Models Mol. Ther. Nucleic Acids 9, 251\u2013262 (2017).","journal-title":"Models Mol. Ther. Nucleic Acids"},{"key":"59015_CR28","first-page":"1071","volume":"22","author":"CW Wu","year":"2002","unstructured":"Wu, C. W. et al. Clinical significance of AXL kinase family in gastric cancer. Anticancer Res. 22, 1071\u20131078 (2002).","journal-title":"Anticancer Res."},{"key":"59015_CR29","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1089\/10445490360708946","volume":"22","author":"BI Chung","year":"2003","unstructured":"Chung, B. I., Malkowicz, S. B., Nguyen, T. B., Libertino, J. A. & McGarvey, T. W. Expression of the proto-oncogene AXL in renal cell carcinoma. DNA Cell Biol. 22, 533\u2013540 (2003).","journal-title":"DNA Cell Biol."},{"key":"59015_CR30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000520501","volume":"11","author":"CH Hsu","year":"2022","unstructured":"Hsu, C. H., Huang, Y. H., Lin, S. M. & Hsu, C. AXL and MET in hepatocellular carcinoma: a systematic literature review. Liver Cancer 11, 94\u2013112 (2022).","journal-title":"Liver Cancer"},{"key":"59015_CR31","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1158\/0008-5472.CAN-10-2186","volume":"71","author":"E Avilla","year":"2011","unstructured":"Avilla, E. et al. Activation of TYRO3\/AXL tyrosine kinase receptors in thyroid cancer. Cancer Res. 71, 1792\u20131804 (2011).","journal-title":"Cancer Res."},{"key":"59015_CR32","doi-asserted-by":"publisher","first-page":"107291","DOI":"10.1016\/j.lungcan.2023.107291","volume":"182","author":"S Bhalla","year":"2023","unstructured":"Bhalla, S. et al. Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer. Lung Cancer 182, 107291 (2023).","journal-title":"Lung Cancer"},{"key":"59015_CR33","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1158\/1078-0432.CCR-10-0574","volume":"16","author":"JP Eder","year":"2010","unstructured":"Eder, J. P. et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin. Cancer Res. 16, 3507\u20133516 (2010).","journal-title":"Clin. Cancer Res."},{"key":"59015_CR34","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","volume":"35","author":"M Mori","year":"2017","unstructured":"Mori, M. et al. Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest. New Drugs 35, 556\u2013565 (2017).","journal-title":"Invest. New Drugs"},{"key":"59015_CR35","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1021\/jm801586s","volume":"52","author":"GM Schroeder","year":"2009","unstructured":"Schroeder, G. M. et al. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2 dihy-dropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J. Med. Chem. 52, 1251\u20131254 (2009).","journal-title":"J. Med. Chem."},{"key":"59015_CR36","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes, F. M. et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 10, 2298\u20132308 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"59015_CR37","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1021\/ml200198x","volume":"2","author":"A Mollard","year":"2011","unstructured":"Mollard, A. et al. Synthesis and biological evaluation of a series of novel AXL kinase inhibitors. ACS Med. Chem. Lett. 2, 907\u2013912 (2011).","journal-title":"ACS Med. Chem. Lett."},{"key":"59015_CR38","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","volume":"616","author":"AV Sadybekov","year":"2023","unstructured":"Sadybekov, A. V. & Katritch, V. Computational approaches streamlining drug discovery. Nature 616, 673\u2013685 (2023).","journal-title":"Nature"},{"key":"59015_CR39","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/ph18030436","volume":"18","author":"DP Mihai","year":"2025","unstructured":"Mihai, D. P. & Nitulescu, G. M. Computer-aided drug design and drug discovery. Pharmaceuticals 18, 436 (2025).","journal-title":"Pharmaceuticals"},{"key":"59015_CR40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12982-024-00229-3","volume":"21","author":"RBO Ouma","year":"2024","unstructured":"Ouma, R. B. O., Ngari, S. M. & Kibet, J. K. A review of the current trends in computational approaches in drug design and metabolism. Discov. Public Health 21, 108 (2024).","journal-title":"Discov. Public Health"},{"key":"59015_CR41","doi-asserted-by":"publisher","first-page":"100321","DOI":"10.1016\/j.jics.2021.100321","volume":"99","author":"IO Adedotun","year":"2022","unstructured":"Adedotun, I. O. et al. Molecular docking ADMET analysis, and bioactivity studies of phytochemicals from Phyllanthus niruri as potential inhibitors of hepatitis C virus NSB5 polymerase. J. Indian Chem. Soc. 99, 100321 (2022).","journal-title":"J. Indian Chem. Soc."},{"key":"59015_CR42","doi-asserted-by":"publisher","first-page":"15705","DOI":"10.1074\/jbc.M116.771485","volume":"292","author":"KS Gajiwala","year":"2017","unstructured":"Gajiwala, K. S. et al. The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase. J. Biol. Chem. 292, 15705\u201315716 (2017).","journal-title":"J. Biol. Chem."},{"key":"59015_CR43","doi-asserted-by":"publisher","first-page":"107116","DOI":"10.1016\/j.mtcomm.2023.107116","volume":"37","author":"F Ozsoy","year":"2023","unstructured":"Ozsoy, F. et al. Self-assembled silibinin-containing phosphazene\/cystamine hybrid nanospheres as biodagradable dual-drug carriers with improved anticancer activity on a breast cancer cell line. Mater. Today Commun. 37, 107116 (2023).","journal-title":"Mater. Today Commun."},{"issue":"17","key":"59015_CR44","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1080\/08927022.2018.1515484","volume":"44","author":"CN Patel","year":"2018","unstructured":"Patel, C. N. & Narechania, M. B. Targeting epidermal growth factor receptors inhibition in non-small-cell lung cancer: a computational approach. Mol. Simul. 44(17), 1478\u20131488 (2018).","journal-title":"Mol. Simul."},{"key":"59015_CR45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4172\/2329-9533.1000142","volume":"6","author":"G Fatima","year":"2017","unstructured":"Fatima, G., Loubna, A., Wiame, L. & Azeddine, I. In silico inhibition studies of AXL kinase by curcumin and its natural derivatives. J. Appl. Bioinform. Comput. Biol. 6, 2 (2017).","journal-title":"J. Appl. Bioinform. Comput. Biol."},{"key":"59015_CR46","doi-asserted-by":"publisher","first-page":"5894","DOI":"10.3390\/ijms24065894","volume":"24","author":"LS Farhoumand","year":"2023","unstructured":"Farhoumand, L. S. et al. Blockade of \u00df-adrenergic receptors by nebivolol enables tumor control potential for uveal melanoma in 3D tumor spheroids and 2D cultures. Int. J. Mol. Sci. 24, 5894 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"59015_CR47","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1038\/s41467-020-17384-1","volume":"11","author":"C Nuevo-Tapioles","year":"2020","unstructured":"Nuevo-Tapioles, C. et al. Coordinate \u03b2-adrenergic inhibition of mitochondrial activity and angiogenesis arrest tumor growth. Nat. Commun. 11(1), 3606 (2020).","journal-title":"Nat. Commun."},{"key":"59015_CR48","first-page":"1049640","volume":"13","author":"NM Abdulkareem","year":"2022","unstructured":"Abdulkareem, N. M. et al. Screening of GPCR drugs for repurposing in breast cancer Front. Pharmacol. 13, 1049640 (2022).","journal-title":"Pharmacol."},{"issue":"3","key":"59015_CR49","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1080\/07391102.2023.2291830","volume":"43","author":"S Kalin","year":"2025","unstructured":"Kalin, S. & Comert Onder, F. Discovery of potential RSK1 inhibitors for cancer therapy using virtual screening, molecular docking, molecular dynamics simulation, and MM\/GBSA calculations. J. Biomol. Struct. Dyn. 43(3), 1424\u20131444. https:\/\/doi.org\/10.1080\/07391102.2023.2291830 (2025).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"59015_CR50","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"GM Sastry","year":"2013","unstructured":"Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 27, 221\u2013234 (2013).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"59015_CR51","doi-asserted-by":"publisher","first-page":"109774","DOI":"10.1016\/j.cbi.2021.109774","volume":"353","author":"K Bhadresha","year":"2022","unstructured":"Bhadresha, K. et al. Theaflavin-3-gallate, a natural antagonist for Hsp 90: In-silico and in-vitro approach. Chem. Biol. Interact. 353, 109774 (2022).","journal-title":"Chem. Biol. Interact."},{"key":"59015_CR52","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner, R. A. et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49, 6177\u20136196 (2006).","journal-title":"J. Med. Chem."},{"key":"59015_CR53","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10822-007-9133-z","volume":"21","author":"JC Shelley","year":"2007","unstructured":"Shelley, J. C. et al. Epik: a software program for pK( a ) prediction and protonation state generation for drug-like molecules. J. Comput. Aided Mol. Des. 21, 681\u2013691 (2007).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"59015_CR54","doi-asserted-by":"crossref","unstructured":"K. J. Bowers, E. Chow, H. Xu, R. O. Dror, M. P. Eastwood, B. A. Gregersen and D. E. Shaw (2006) Scalable algorithms for molecular dynamics simulations on commodity clusters. In Proceedings of the 2006 ACM\/IEEE Conference on Supercomputing, IEEE, Tampa, p. 84.","DOI":"10.1145\/1188455.1188544"},{"issue":"48","key":"59015_CR55","doi-asserted-by":"publisher","first-page":"e05605","DOI":"10.1002\/slct.202505605","volume":"10","author":"M S\u0131k\u0131k","year":"2025","unstructured":"S\u0131k\u0131k, M. & Comert Onder, F. Repurposing of FDA-approved drugs as acetylcholinesterase inhibitors for Alzheimer\u2019s disease: A combined in silico and in vitro evaluation and structure-activity relationship. ChemistrySelect 10(48), e05605 (2025).","journal-title":"ChemistrySelect"},{"key":"59015_CR56","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1021\/ja00214a001","volume":"110","author":"WL Jorgensen","year":"1988","unstructured":"Jorgensen, W. L. & Tirado-Rives, J. The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J. Am. Chem. Soc. 110, 1657\u20131666 (1988).","journal-title":"J. Am. Chem. Soc."},{"key":"59015_CR57","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/prot.10613","volume":"55","author":"MP Jacobson","year":"2004","unstructured":"Jacobson, M. P. et al. \u201cA hierarchical approach to all-atom protein loop prediction\u201d, Proteins: Structure. Funct. Bioinformat. 55, 351\u2013367 (2004).","journal-title":"Funct. Bioinformat."},{"key":"59015_CR58","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1021\/acsptsci.1c00030","volume":"4","author":"F Comert Onder","year":"2021","unstructured":"Comert Onder, F. et al. Target-driven design of a coumarinyl chalcone scaffold based novel EF2 kinase inhibitor suppresses breast cancer growth in vivo ACS. Pharmacol. Transl. Sci. 4, 926\u2013940 (2021).","journal-title":"Pharmacol. Transl. Sci."},{"key":"59015_CR59","doi-asserted-by":"crossref","unstructured":"Onder, F. C., Kahraman, N., Siyah, P., Durda\u011f\u0131, S., Atici, E. B., Atalay, P., & Ozpolat, B. Computational discovery and preclinical validation of a novel nanodrug eEF2 kinase inhibitor for suppression of tumor growth in triple-negative breast cancer by induction of ferroptosis and apoptosis. Int. J. Biol. Macromol. 151860. (2026).","DOI":"10.1016\/j.ijbiomac.2026.151860"},{"issue":"48","key":"59015_CR60","doi-asserted-by":"publisher","first-page":"e202304614","DOI":"10.1002\/slct.202304614","volume":"8","author":"F Comert Onder","year":"2023","unstructured":"Comert Onder, F., Sahin, N., Davutlar, G., Onder, A. & Ay, M. Nitro compounds inhibit breast cancer cell proliferation, migration, and colony formation: molecular docking, molecular dynamics simulations and pharmacological properties. ChemistrySelect 8(48), e202304614 (2023).","journal-title":"ChemistrySelect"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59015-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59015-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59015-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:01:56Z","timestamp":1789434116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59015-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["59015"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-59015-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"28668"}}